321 related articles for article (PubMed ID: 27460064)
1. Concepts in glioma immunotherapy.
Platten M; Bunse L; Wick W; Bunse T
Cancer Immunol Immunother; 2016 Oct; 65(10):1269-75. PubMed ID: 27460064
[TBL] [Abstract][Full Text] [Related]
2. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
3. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
4. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
5. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
7. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.
Hofman FM; Stathopoulos A; Kruse CA; Chen TC; Schijns VE
Anticancer Agents Med Chem; 2010 Jul; 10(6):462-70. PubMed ID: 20879986
[TBL] [Abstract][Full Text] [Related]
9. Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R
Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of diffuse gliomas: biological background, current status and future developments.
Grauer OM; Wesseling P; Adema GJ
Brain Pathol; 2009 Oct; 19(4):674-93. PubMed ID: 19744040
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
14. Concepts for Immunotherapies in Gliomas.
Platten M; Reardon DA
Semin Neurol; 2018 Feb; 38(1):62-72. PubMed ID: 29548053
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
19. Principles of immunotherapy.
Liebelt BD; Finocchiaro G; Heimberger AB
Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
[TBL] [Abstract][Full Text] [Related]
20. Concepts of immunotherapy for glioma.
Patel MA; Pardoll DM
J Neurooncol; 2015 Jul; 123(3):323-30. PubMed ID: 26070552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
